NasdaqGM - Nasdaq Real Time Price USD

TransMedics Group, Inc. (TMDX)

Compare
84.97 +2.57 (+3.12%)
At close: 4:00 PM EST
84.00 -0.97 (-1.14%)
After hours: 6:07 PM EST
Loading Chart for TMDX
DELL
  • Previous Close 82.40
  • Open 82.14
  • Bid 84.86 x 300
  • Ask 85.03 x 400
  • Day's Range 81.74 - 85.29
  • 52 Week Range 40.01 - 177.37
  • Volume 1,445,794
  • Avg. Volume 1,365,739
  • Market Cap (intraday) 2.852B
  • Beta (5Y Monthly) 1.99
  • PE Ratio (TTM) 91.37
  • EPS (TTM) 0.93
  • Earnings Date Oct 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 139.25

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com

584

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMDX

View More

Performance Overview: TMDX

Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMDX
7.65%
S&P 500
19.77%

1-Year Return

TMDX
99.37%
S&P 500
31.07%

3-Year Return

TMDX
191.59%
S&P 500
22.57%

5-Year Return

TMDX
335.52%
S&P 500
86.27%

Compare To: TMDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMDX

View More

Valuation Measures

Annual
As of 11/1/2024
  • Market Cap

    2.77B

  • Enterprise Value

    2.95B

  • Trailing P/E

    88.60

  • Forward P/E

    51.55

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.10

  • Price/Book (mrq)

    13.17

  • Enterprise Value/Revenue

    7.36

  • Enterprise Value/EBITDA

    45.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.14%

  • Return on Assets (ttm)

    2.84%

  • Return on Equity (ttm)

    19.41%

  • Revenue (ttm)

    401.09M

  • Net Income Avi to Common (ttm)

    32.64M

  • Diluted EPS (ttm)

    0.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    330.09M

  • Total Debt/Equity (mrq)

    246.83%

  • Levered Free Cash Flow (ttm)

    -142.59M

Research Analysis: TMDX

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 108.76M
Earnings 4.22M
Q4'23
Q1'24
Q2'24
Q3'24
0
20M
40M
60M
80M
100M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

87.00
139.25 Average
84.97 Current
180.00 High
 

Company Insights: TMDX

Research Reports: TMDX

View More
  • Rating increased to a HOLD

    TRANSMEDICS GROUP INC has an Investment Rating of HOLD; a target price of $93.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
     
  • Lowering target price to $98.00

    TRANSMEDICS GROUP INC has an Investment Rating of SELL; a target price of $98.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Lowering target price to $105.00

    TRANSMEDICS GROUP INC has an Investment Rating of SELL; a target price of $105.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Rating decreased to a SELL

    TRANSMEDICS GROUP INC has an Investment Rating of SELL; a target price of $110.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch